- Home
- LUXH vs NRXP Comparison
LUXH vs NRXP Comparison
Compare LUXH & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUXH
- NRXP
- Stock Information
- Founded
- LUXH 2017
- NRXP 2015
- Country
- LUXH United States
- NRXP United States
- Employees
- LUXH N/A
- NRXP N/A
- Industry
- LUXH Real Estate
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- LUXH Finance
- NRXP Health Care
- Exchange
- LUXH Nasdaq
- NRXP Nasdaq
- Market Cap
- LUXH 12.7M
- NRXP 14.8M
- IPO Year
- LUXH N/A
- NRXP N/A
- Fundamental
- Price
- LUXH $0.04
- NRXP $1.17
- Analyst Decision
- LUXH Hold
- NRXP Strong Buy
- Analyst Count
- LUXH 2
- NRXP 3
- Target Price
- LUXH N/A
- NRXP $31.33
- AVG Volume (30 Days)
- LUXH 33.9M
- NRXP 153.3K
- Earning Date
- LUXH 11-26-2024
- NRXP 11-18-2024
- Dividend Yield
- LUXH N/A
- NRXP N/A
- EPS Growth
- LUXH N/A
- NRXP N/A
- EPS
- LUXH N/A
- NRXP N/A
- Revenue
- LUXH $90,865,323.00
- NRXP N/A
- Revenue This Year
- LUXH N/A
- NRXP N/A
- Revenue Next Year
- LUXH $15.51
- NRXP N/A
- P/E Ratio
- LUXH N/A
- NRXP N/A
- Revenue Growth
- LUXH 14.73
- NRXP N/A
- 52 Week Low
- LUXH $0.03
- NRXP $1.10
- 52 Week High
- LUXH $6.88
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- LUXH 38.97
- NRXP 32.50
- Support Level
- LUXH $0.04
- NRXP $1.12
- Resistance Level
- LUXH $0.04
- NRXP $1.30
- Average True Range (ATR)
- LUXH 0.01
- NRXP 0.09
- MACD
- LUXH 0.00
- NRXP -0.00
- Stochastic Oscillator
- LUXH 17.33
- NRXP 6.06
About LUXH LuxUrban Hotels Inc.
LuxUrban Hotels Inc utilizes a long term lease, asset-light business model to acquire and manage a growing portfolio of short-term rental properties in metropolitan cities. It identifies, acquires, manages, and markets hotel rooms to business and vacation travelers under the consumer brand, LuxUrban. It manages a portfolio of hotel rooms in New York, Washington D.C., Miami Beach, New Orleans and Los Angeles.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.